433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial

Igor Puzanov,Parminder Singh,Merrick Ross,Celeste Lebbe,Philip Friedlander,Min Yi,Mohammed Milhem,Frances Collichio,Omid Hamid,Axel Hauschild,Claus Garbe,Jason Chesney,Wendy Snyder,John Glaspy,Theodore Logan,Janice Mehnert

doi:10.1136/jitc-2020-sitc2020.0433

433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial

Igor Puzanov, Parminder Singh + Show 14 more

Open Access

https://doi.org/10.1136/jitc-2020-sitc2020.0433

Copy DOI

Journal: Journal for ImmunoTherapy of Cancer	Publication Date: Nov 1, 2020
Citations: 5	License type: open-access

Affiliation: Roswell Park Cancer Institute, Mayo Clinic, The University of Texas MD Anderson Cancer Center, Mount Sinai Hospital, Amgen (United States), University of Iowa Hospitals and Clinics, University of North Carolina at Chapel Hill, Angeles Clinic and Research Institute, Kiel University, James Graham Brown Foundation, University of California, Los Angeles, Indiana University Health, Indiana University – Purdue University Indianapolis, Rutgers, The State University of New Jersey

#Talimogene Laherparepvec In Combination #Durable Response Rate + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundThis is the first randomized trial evaluating an oncolytic virus with an immune checkpoint inhibitor in advanced melanoma. Improved objective response rate (ORR) was observed for T-VEC plus IPI compared...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.